Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Colorectal Cancer, Healthy Lifestyle, Behavior, Health, Health Behavior, Gastrointestinal Cancers
Interventions: RISE Personalized Self-Management Training (PSMT), Standardized Self-Management Training (SSMT); Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Cesarean Section
Interventions: Insorb absorbable staples, Insorb; Device
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 1 Diabetes
Interventions: MiniMed Paradigm REAL-Time System; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 7 Years to 70 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 26
States / cities: La Jolla, California • Orange, California • Boulder, Colorado + 23 more

Conditions: Asthma
Interventions: HXe MRI guided treatment sequence for BT, Standard treatment sequence for BT (control); Drug · Other
Lead sponsor: Xemed LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anterior Uveitis
Interventions: 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more

Conditions: Hiv, Mental Health Issue
Interventions: STEP-AD, Enhanced treatment as usual (E-TAU); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions: Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent; Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Placebo, Xolair; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Overactive Bladder
Interventions: Oxybutynin topical gel, Placebo topical gel; Drug · Other
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Renal Impairment
Interventions: Tasimelteon; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Stage 1 Pressure Ulcer, Stage 2 Pressure Ulcer
Interventions: Intermittent electrical stimulation system (IES) treatment and turning patient every two hours, Turning population every two hours; Device · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Cleveland, Ohio

Conditions: HIV Infections
Interventions: Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1996
U.S. locations: 3
States / cities: St Louis, Missouri • Rochester, New York • Seattle, Washington

Conditions: Low Back Pain
Interventions: Motor Imagery. Imaging doing Extension exercises without actually doing them., Control: Physically performing extension based exercises.; Other
Lead sponsor: St. Ambrose University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Naperville, Illinois • Davenport, Iowa

Conditions: PTSD
Interventions: NYX-783, Placebo; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 33 more

Conditions: Multiple Sclerosis
Interventions: NAbs testing; Procedure
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 49
States / cities: Phoenix, Arizona • Berkley, California • Fresno, California + 43 more

Conditions: Schizophrenia, Schizo Affective Disorder, Social Skills
Interventions: social VR (virtual reality) training, Cognitive training (control game); Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis, Polyarthritis, Avascular Necrosis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee
Interventions: Cementless Persona Knee System, Cemented Persona Knee System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 7
States / cities: Westminster, Colorado • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Opioid Use Disorder (OUD)
Interventions: Communities That HEAL, Wait-list control; Other
Lead sponsor: RTI International; Other
Eligibility: Not listed
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Lexington, Kentucky • Boston, Massachusetts • New York, New York + 1 more

Conditions: Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Fresno, California

Conditions: Hypertension
Interventions: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Tularaemia
Interventions: Placebo, Undiluted Francisella tularensis live attenuated vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption, Pain After Surgery
Interventions: Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Hemophilia A
Interventions: Recombinant Protein-Free Factor VIII (rAHF-PFM); Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Search by objective public record fields.

Personalized Health Self-Management Training for Colorectal Cancer Survivors

A Comparison of Metallic Staples Versus Absorbable Staples After a Cesarean Section (C-Section)

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Striving Towards EmPowerment and Medication Adherence R01

Truway Diagnostic Tools in Primary Care

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

The PROTECT 2 Study : Pressure Injury Treatment by Intermittent Electrical Stimulation: A Randomized, Controlled Trial

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

RCT of Motor Imagery of Extension for LBP vs. Exercise

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training

Cemented vs Cementless Persona Keel RCT

HEALing Communities Study

Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Phase II Tularemia Vaccine Comparison

Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery